Research ArticleTolerability and pharmacokinetics of ginsenosides Rb1, Rb2, Rc, Rd, and compound K after single or multiple administration of red ginseng extract in human beings
-
Add time:08/22/2019 Source:sciencedirect.com
BackgroundWe investigated the tolerability and pharmacokinetic properties of various ginsenosides, including Rb1, Rb2, Rc, Rd, and compound K, after single or multiple administrations of red ginseng extract in human beings.
We also recommend Trading Suppliers and Manufacturers of GINSENOSIDE RB2 (cas 11021-13-9). Pls Click Website Link as below: cas 11021-13-9 suppliers
Prev:Research ArticleGinsenoside Rb1 and Rb2 upregulate Akt/mTOR signaling–mediated muscular hypertrophy and myoblast differentiation
Next:Full Length ArticleLincomycin–embedded PANI–based coatings for biomedical applications) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research ArticleGinsenoside Rb1 and Rb2 upregulate Akt/mTOR signaling–mediated muscular hypertrophy and myoblast differentiation08/21/2019
- Original articleGINSENOSIDE RB2 (cas 11021-13-9) inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway08/20/2019
- GINSENOSIDE RB2 (cas 11021-13-9) promotes glucose metabolism and attenuates fat accumulation via AKT-dependent mechanisms08/19/2019
- Research articleHighly regioselective biotransformation of GINSENOSIDE RB2 (cas 11021-13-9) into compound Y and compound K by β-glycosidase purified from Armillaria mellea mycelia08/18/2019
- GINSENOSIDE RB2 (cas 11021-13-9) inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling08/17/2019
- Research ArticleGINSENOSIDE RB2 (cas 11021-13-9) suppresses the glutamate-mediated oxidative stress and neuronal cell death in HT22 cells08/16/2019
-
Health and Chemical more >